An economic evaluation of vaccination against hepatitis A for frequent travellers.
This paper compares the cost of using inactive Hepatitis A vaccine relative to immunoglobulin as a means of protecting frequent travellers against Hepatitis A. The number of trips to 'at risk' areas is modelled as a Poisson process and results are reported in terms of the discounted gross cost per protected trip over a 10-year period. We find that the expected cost of immunization is lower with immunoglobulin for travellers visiting 'at risk' areas less than five times in 10 years, and lower with Hepatitis A vaccine for those visiting 'at risk' areas more than five times in 10 years.
Fenn
P
P
School of Management and Finance, University of Nottingham, UK.
McGuire
A
A
Gray
A
A
D003362:Cost-Benefit Analysis; D006506:Hepatitis A / Q000191:economics* / Q000517:prevention & control / Q000635:transmission; D022362:Hepatitis A Vaccines; D006801:Humans; D008954:Models, Biological; D012680:Sensitivity and Specificity; D014195:Travel; D014611:Vaccination / Q000191:economics*; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000191:economics; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage / Q000191:economics*
D022362:Hepatitis A Vaccines; D015164:Vaccines, Inactivated; D014761:Viral Hepatitis Vaccines